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ABSTRACT
A Histamine H3 receptor antagonist, ciproxifan has been shown to enhance the release
of neurotransmitters which play an important role in cognitive process. It is widely
documented that extracellular deposition of ~-amyloidpeptide (A~) plays a causal role
in the pathogenesis -of AD. However, the role of ciproxifan on A~ has not been well
documented. The present study was aimed to investigate the ability of ciproxifan to
inhibit BACE-l activity and to determine the neuroprotective effect of ciproxifan on
A~ in vitro. Furthermore, the effect of ciproxifan on the AD related biomarkers was
also investigated using APP(Sw) transgenic mice of AD model. The BACE-l
inhibition activity was carried out using BACE-l assay kit while the SK-N-SH cells
were induced with AP25-35 prior to the treatment with ciproxifan and then cell viability
as well as ROS assay also was determined. For in vivo study, ciproxifan was
administrated to the mice by intraperitoneal injection (i.p) for 15 days with two
selective doses (1 and 3 mg/kg) and spatial learning and memory behaviour were
assessed using radial arm maze (RAM). Brain tissues were collected to measure
acetylcholine (ACh), acetylcholinesterase (AChE), nitric oxide (NO), lipid
peroxidation (LPO), antioxidant activities, cyclooxygenase (COX) and pro-
inflammatory cytokines assay while plasma were collected to measure an anti-
inflammatory cytokine TGF-I p. The results for in vitro study demonstrated that
ciproxifan weakly inhibited BACE-I activity with IC50BAcE 500 11g/m1 and showed
neuroprotective effect by increasing the cell viability and inhibited the production of
ROS and these effects were comparable with positive control u-tocopherol.
Meanwhile, ciproxifan significantly reduced time taken of the mouse to consume all
five baits, working memory error and reference memory error in RAM. Ciproxifan did
not show any alteration on the level of both ABI-40 and A~142 in APP transgenic mice.
Ciproxifan also elevated the level of ACh while reduced AChE activity and showed
anti-oxidant properties by reducing NO and LPG levels as well as enhancing the level
of antioxidants (catalase, aSH and GPx). Moreover, the results of neuroinflammatory
analysis showed that ciproxifan reduced both COX-I and COX-2 activities, decreased
the level of pro-inflammatory cytokines IL-I (1, IL-I ~ and IL-6 and increased the level
of anti-inflammatory cytokine TGF-I~. In conclusion, the present study suggests that
ciproxifan possessed neuroprotective effect against A~ and could protect the SK-N-
SH cells from Ajl-induced toxicity by preventing the cell death through the inhibition
of oxidative stress. However, protective effects of ciproxifan probably were not
through the inhibition of BACE-l activity and the reduction of Ap level but by other
mechanism. The ameliorative effect of ciproxifan on memory deficit of APP
transgenic mice may be mediated through improving cholinergic, antioxidant and anti-
inflammatory activities. This present study may provide some scientific evidences of
ciproxifan through various mechanisms as a promising agent for the treatment of AD.
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